Compare ICMB & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | FEMY |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.8M | 35.4M |
| IPO Year | N/A | 2021 |
| Metric | ICMB | FEMY |
|---|---|---|
| Price | $2.78 | $0.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 23.4K | ★ 1.3M |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | ★ 18.74% | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $17,931,778.00 | $2,061,502.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | $4.75 | $147.19 |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | N/A | ★ 63.53 |
| 52 Week Low | $2.46 | $0.31 |
| 52 Week High | $3.47 | $1.80 |
| Indicator | ICMB | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 42.57 |
| Support Level | $2.75 | $0.60 |
| Resistance Level | $2.89 | $0.73 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 65.00 | 28.06 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.